Association of plasma S100A12 level with cardiovascular diseases.

在终末期肾病（ESRD）患者中，我们发现平均血浆S100A12水平比对照组高2.3倍，并且该水平是动脉粥样硬化性心血管疾病（CVD）患病率的独立因素，如缺血性心脏病（包括心肌梗死和心绞痛）、症状性卒中和症状性周围血管疾病。因此，我们预计S100A12作为一种新的生物标志物在预测ESRD患者的CVD方面具有重要作用。目前正在进行前瞻性和介入性研究，以进一步阐明血浆S100A12水平与CVD之间的关系。

In end stage renal disease(ESRD) patients, we found that mean plasma S100A12 level was 2.3-fold higher than that in control subjects and that this level was an independent factorassociated with the prevalence of atherosclerotic cardiovascular diseases(CVD) such as ischemic heart disease including myocardial infarction and angina pectoris, symptomatic stroke and symptomatic peripheral vascular disease. Therefore, we anticipate an important role for S100A12 as a novel biomarker to predict CVD in patients with ESRD. Prospective and interventional studies are currently ongoing to further elucidate the relationship between plasma S100A12 level and CVD.